-
公开(公告)号：WO2023086897A1
公开(公告)日：2023-05-19
申请号：PCT/US2022/079656
申请日：2022-11-10
摘要： The invention provides antibodies, antibody -based fragments or antibody fragments (antigen-binding fragments), as well as derivative molecules such as bispecific T- cell engagers, antibody-drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize Siglec-6 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.
-
公开(公告)号：WO2023077037A1
公开(公告)日：2023-05-04
申请号：PCT/US2022/078830
申请日：2022-10-27
发明人： DISNEY, Matthew, D.
IPC分类号： A61K31/475 , A61P25/28 , C07D333/38
摘要： Described are small molecule embodiments, ALS compounds, that bind with the r(G4C2)exp RNA repeat expansion present in chromosome 9 open reading frame 72 involved in amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD). These ALS compounds comprise a pyridocarbazole moiety having at least one substituent and an RNase- recruiting moiety linked to the pyridocarbazole moiety by a polyethylene glycol group.
-
公开(公告)号：WO2023064326A1
公开(公告)日：2023-04-20
申请号：PCT/US2022/046367
申请日：2022-10-12
发明人： ZHOU, Daohong , ZHENG, Guangrong , HE, Yonghan , PI, Liya
IPC分类号： C07D417/14 , A61P3/10 , A61P35/00
摘要： Disclosed herein are methods of treating diseases and disorders associated with senescent cell accumulation (e.g., an age-related disease and/or liver disease, e.g., obesity, liver steatosis, non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, or hepatocellular carcinoma (HCC)) and methods of ameliorating insulin resistance, pre-diabetes, or diabetes. Also disclosed herein are methods of degrading B-cell lymphoma-2 (Bcl-2) and/or B-cell lymphoma-extra large (Bcl-xl) proteins and methods of killing a senescent cell.
-
公开(公告)号：WO2023060194A1
公开(公告)日：2023-04-13
申请号：PCT/US2022/077696
申请日：2022-10-06
IPC分类号： A61K35/17 , A61K39/00 , A61P37/00 , C07K14/725 , C07K16/28
摘要： Disclosed herein are compositions comprising engineered antigen-specific Tregs that suppress antibody formation against the soluble therapeutic protein factor VIII in an MHC-independent fashion. Complexing TCR-based signaling with single-chain variable fragment (scFv) recognition to generate TCR fusion construct (TRuC)-Tregs delivered controlled antigen-specific signaling via engagement of the entire TCR complex, thereby directing functional suppression of the FVIII-specific antibody response.
-
公开(公告)号：WO2023031939A1
公开(公告)日：2023-03-09
申请号：PCT/IL2022/050965
申请日：2022-09-05
申请人： THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI INSTITUTE) , UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED , UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
发明人： RAVEH, Eran , ALBRECHT, Ute , BOWMAN, Kim D. , TIETEL, Zipora
摘要： A composition comprising an HLB -susceptible or tolerant citrus rootstock grafted with an HLB -tolerant or resistant citrus interstock is provided. Also provided are plants comprising same and uses thereof in citrus growth.
-
公开(公告)号：WO2023028035A1
公开(公告)日：2023-03-02
申请号：PCT/US2022/041176
申请日：2022-08-23
发明人： MCKENNA, Robert , MIETZSCH, Mario , HULL, Joshua
IPC分类号： A61K35/761 , C12N15/861 , A61P35/00 , C07K14/005
摘要： The disclosure relates to lipid enveloped rAAV particles, compositions comprising the same, and methods of treating a disease comprising the administration of such lipid enveloped rAAV peptides and compositions. Methods of preparing populations of lipid enveloped rAAV particles are also disclosed. Wherein the AAV can be AAV serotype 1 (AAV1), and the compositoin includes a pharmacuetically-accpetable carrier or excipient.
-
公开(公告)号：WO2023023525A1
公开(公告)日：2023-02-23
申请号：PCT/US2022/075033
申请日：2022-08-16
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
发明人： HO, Chih-Ming , KHONG, Jeffrey , LEE, Megan , ZARRINPAR, Ali , KIM, Un Bi , WARREN, Curtis
摘要： The present disclosure includes systems and methods for calculating a dosage of one or more medications. Some aspects include determining a dosage for a patient after an organ transplant, at least by determining a first dosage of a drug given to a patient on a first day, determining a first serum level of the patient associated with the first day, calculating a second dosage of the drug based on a first ratio between the first dosage and the first serum level, and generating a first output based on the second dosage. Some aspects include determining a fourth dosage of the drug based on: a second ratio between the second dosage and a second serum level and a third ratio between a third dosage and a third serum level. Some aspects include generating a second output based on the fourth dosage, the fourth dosage associated with a fourth time period.
-
公开(公告)号：WO2023022976A1
公开(公告)日：2023-02-23
申请号：PCT/US2022/040326
申请日：2022-08-15
申请人： UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED , ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. , UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
IPC分类号： C12Q1/6886 , A61P35/02
摘要： The disclosure relates to methods for characterizing and/or treating a subject having cancer, said methods comprising performing an assay to identify the nucleotides present at each of a set of single-nucleotide polymorphism (SNP) locations within the cytarabine (ara-C) pathway, assigning a genotype score for the identified nucleotides of each SNP, and characterizing the subject having cancer based on the summation of the assigned genotype scores. In some embodiments, treatment is administered based upon the characterization of the subject, according to the methods described herein.
-
公开(公告)号：WO2023010120A2
公开(公告)日：2023-02-02
申请号：PCT/US2022/074316
申请日：2022-07-29
摘要： Provided herein are modified adeno-associated virus (AAV) capsid proteins, particles, nucleic acid vectors, and compositions thereof, as well as methods of their use, such as in the treatment of neurological diseases and disorders. Specifically, the disclosure provides a modified AAV capsid protein comprising a non-native peptide within loop IV or loop VIII of the capsid protein. Further provided are non- native peptide sequences for insertion.
-
公开(公告)号：WO2023278510A1
公开(公告)日：2023-01-05
申请号：PCT/US2022/035428
申请日：2022-06-29
申请人： UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED , ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY , THE PENN STATE RESEARCH FOUNDATION
IPC分类号： A61B5/00
摘要： An olfactory test comprising an olfactory test article including a plurality of trials that each has an associated concentration of a stimulus of interest. Aspects of the present disclosure further relate to software application that guides a user through conducting the olfactory test based at least in part on the user's responses to trials of the olfactory test article, such that the user can be guided through a custom order of trials, and therefore different concentrations of the stimuli of interest, based at least in part on the user's responses to the trials as the user performs the olfactory test.
-
-
-
-
-
-
-
-
-
搜索结果
2336 条记录 (耗时 0.052 秒)
